Repligen (Repligen) Common Stock : $0.6 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Repligen Common Stock?

Repligen's quarterly common stock increased from Jun. 2023 ($0.6 Mil) to Sep. 2023 ($0.6 Mil) but then stayed the same from Sep. 2023 ($0.6 Mil) to Dec. 2023 ($0.6 Mil).

Repligen's annual common stock increased from Dec. 2021 ($0.6 Mil) to Dec. 2022 ($0.6 Mil) and increased from Dec. 2022 ($0.6 Mil) to Dec. 2023 ($0.6 Mil).

Repligen Common Stock Historical Data

The historical data trend for Repligen's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Repligen Common Stock Chart

Repligen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.52

0.55

0.56

Repligen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Common Stock	Get a 7-Day Free Trial															0.56	0.56	0.56	0.56	0.56

Repligen Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Repligen (Repligen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Repligen Corp (NAS:RGEN) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

RGN:Germany RGN:Germany

Address

41 Seyon Street, Building 1, Suite 100, Waltham, MA, USA, 02453

Website

https://www.repligen.com

Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.

Executives

Christine Gebski	officer: See Remarks	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. 1, SUITE 100, WALTHAM MA 02453
Olivier Loeillot	officer: President and CCO	C/O REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453
Jason K Garland	officer: CFO	10000 WEHRLE DRIVE, CLARENCE NY 14031
Karen A Dawes	director	579 BELLEVUE AVE, NEWPORT RI 02840
Martin D Madaus	director	290 CONCORD ROAD, BILLERICA MA 01821
Jon Snodgres	officer: CFO	REPLIGEN CORPORATION, 41 SEYON STREET, BUILDING #1, SUITE 100, WALTHAM MA 02435
Anthony Hunt	director, officer: Chief Executive Officer	41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02452
Ralf Kuriyel	officer: Senior VP, R&D	41 SEYON ST, BLDG 1, STE. 100, WALTHAM MA 02452
James Bylund	officer: SVP, Global Operations & IT	C/O REPLIGEN CORPORATION, 41 SYON ST. BLDG. SUITE 100, WALTHAM MA 02453
Konstantin Konstantinov	director	C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Manner Carrie Eglinton	director	C/O QUEST DIAGNOSTICS, 500 PLAZA DRIVE, SECAUCUS NJ 07094
Ryan Thomas F Jr	director
Nicolas Barthelemy	director	1750 BELLA LAGUNA CT, ENCINITAS CA 92024
John Cox	director	C/O BIOVERATIV INC., 225 SECOND AVENUE, WALTHAM MA 02451
Rohin Mhatre	director	C/O REPLIGEN CORP., 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM MA 02453